Compare Summit Therapeutics Inc (SMMT) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Tripadvisor Inc Common Stock — how do they compare? Summit Therapeutics Inc trades at $17.35 (market cap $13.71B), while Tripadvisor Inc Common Stock trades at $8.68 (market cap $1.01B). The key difference: Summit Therapeutics Inc is far larger — about 13.6× Tripadvisor Inc Common Stock's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Tripadvisor Inc Common Stock for 57 Days on average.
| SMMT | TRIP | |
|---|---|---|
Market Cap | $13.71B | $1.01B |
Volume | 6,173,057 | 3,004,748 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.38 | $16.72 |
52-Week Low | $12.43 | $8.04 |
Typical Hold Time | 16 Days | 57 Days |
Enterprise Value | $13.04B | $1.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
TripAdvisor (TRIP) trades at $8.63, down 42% over the past year and near its 52-week low of $8.27. The stock shows bearish technical signals with recent earnings misses and declining revenue projections for 2026. Despite a low P/S ratio of 0.57, the company faces challenges from AI-driven competition eroding its core travel platform relevance.
The investment outlook remains cautious with analysts divided (21% Buy, 63% Hold) and a $13.58 price target suggesting 57% upside. Key risks include persistent search pressure, TheFork subsidiary sale execution, and competitive threats from AI travel tools. Positive cash flow from operations provides some stability amid the challenging transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
